A Long-term Safety Study of Once-daily Travatan

Alcon

Status and phase: Completed; Phase 3

Conditions: Ocular Hypertension; Glaucoma, Open-angle

Treatments: Drug: Travatan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00051168

C-02-20

Details and patient eligibility

About

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

Enrollment: 502 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

502 participants in 1 patient group

Travatan

Experimental group

Description:

Travoprost (0.004%)

Treatment:

Drug: Travatan